- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03947723
Histology Evaluation of Radiofrequency Ablation
Histologic Evaluation Comparing Power Settings in Radiofrequency Ablation on Eyelash Follicles
Study Overview
Detailed Description
Subject fulfilling the inclusion and exclusion criteria and willing to participate in the study will be enrolled. All participants will receive all 4 treatments at the varying power settings (low, 1, 1.5, 2).
The patients will be prepped for their surgery in the usual fashion. This portion of the procedure is not experimental and is an elective surgery that the patients are choosing to undergo prior to enrolling in the study. This procedure is performed in the operating room. After adequate anesthesia is achieved, subcutaneous 2% lidocaine with epinephrine with 0.5% marcaine, and vitrase is injected into the lower eyelids and lateral canthal areas. The face is prepped and draped in sterile fashion using topical Betadine. A corneal shield will be placed into the fornix at this time. A lateral canthal incision is then made using a #15 blade. Straight Stevens scissors are used to perform a canthotomy and monopolar cautery was used to incise the inferior crus of the lateral canthal tendon. Hemostasis is maintained. The freed lower eyelid is draped over the zygoma. The excess eyelid is then excised full-thickness with Westcott scissors. (If this excess eyelid skin is at least 5 mm on both sides, the study will be performed and the treatments will be applied at this point). The tissue will be marked and divided into 4 equal sections (2 sections on each lid). Each section will be treated with the designated power setting in the following manner.
The probe will be inserted into the follicle under direct visualization to a depth of approximately 1.4 mm. The designated power will be applied for 1 second. All lashes in each segment will be treated. The segments will then be excised and placed into labelled and coded containers of formalin.
Attention will then be directed back to completing the lateral tarsal strip/eyelid surgery. The remainder of the surgery will be performed in the usual fashion and is not part of the experimental portion of the study. One 4-0 Vicryl on P-2 needle is then passed through the tarsus backhanded anterior inferiorly exiting posterior superiorly within the wound and then passed back through the periosteum approximately 3 mm from the orbital rim at the level of the superior crus of the lateral canthal tendon and temporarily tied. This procedure is repeated in full on the other side. The sides are compared. Once the proper contour and tightness is achieved, the suture is permanently tied in a horizontal mattress fashion after passing back through the remnants of the inferior crus. Attention is then turned to the upper lid, whose lateral mucocutaneous junction is trimmed using Westcott scissors. The gray lines of the lateral upper and lower eyelids arre reapposed using 6-0 Vicryl. The lateral canthal incisions are closed with a running 6-0 Prolene suture. Tobradex ointment is applied to the eye and eyelid. The patient is awakened and extubated and taken to the recovery room in stable condition. The patients will be examined at their post-operative week 1 and month 1 visits as per the usual standard of care. After the 1 month visit, their participation in the study is complete.
The tissue sections will be sent to the pathology department for sectioning and staining. The tissue will be sectioned through the follicles. The slides will be stained with hemotoxylin and eosin and Masson-Trichrome. The extent of tissue damage will be measured as the diameter of abnormal/damaged tissue in microns. The severity will be graded on a numerical scale from 0-3. The results will be compared among the 4 power settings.
Study Type
Phase
- Not Applicable
Contacts and Locations
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Undergoing the bilateral tarsal strip procedure
- The procedure requires at least 5 mm of tissue to be excised from each side to provide adequate tightening of the lower eyelids (to be determined intra-operatively)
- Caucasian (to control for any different responses ellicited by the treatment in pigmented skin)
Exclusion Criteria:
- previous treatments for trichiasis along the lateral lower eyelid
- madarosis of eyelashes
- hypertrichosis of eyelashes
- patients undergoing only unilateral tarsal strip procedures
- history of eyelid trauma or chemical burns
- patients with a history of disorders affecting the mucus membranes (ie: Stevens-Johnson syndrome, ocular cicatricial pemphigoid)
- history of eyelid surgery
- history of facial skin cancers
- patients with eyelid lesions affecting the lateral lower eyelids
- patients with active inflammatory ocular diseases (keratitis, scleritis, conjunctivitis, etc).
These exclusion criteria are to generally encompass and exclude any eyelid or eyelash pathology that may confuse what histology changes are from the study treatments versus what pathology was already there at baseline.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Factorial Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Low power
These tissue sections will receive radiofrequency ablation to each eyelash follicle at a power of "low."
|
The eyelid segments to be excised as part of their planned lateral tarsal strip procedure will be marked and divided into 4 equal sections (2 sections on each lid).
A corneal shield will be placed into the fornix prior to treatment.
Each section will be treated with the designated power setting in the following manner.
The probe will be inserted into the follicle under direct visualization to a depth of approximately 1.4 mm.
The designated power will be applied for 1 second.
All lashes in each segment will be treated.
The segments will then be excised and placed into labelled and coded containers of formalin.
|
|
Experimental: 1 power
These tissue sections will receive radiofrequency ablation to each eyelash follicle at a power of 1.
|
The eyelid segments to be excised as part of their planned lateral tarsal strip procedure will be marked and divided into 4 equal sections (2 sections on each lid).
A corneal shield will be placed into the fornix prior to treatment.
Each section will be treated with the designated power setting in the following manner.
The probe will be inserted into the follicle under direct visualization to a depth of approximately 1.4 mm.
The designated power will be applied for 1 second.
All lashes in each segment will be treated.
The segments will then be excised and placed into labelled and coded containers of formalin.
|
|
Experimental: 1.5 power
These tissue sections will receive radiofrequency ablation to each eyelash follicle at a power of 1.5
|
The eyelid segments to be excised as part of their planned lateral tarsal strip procedure will be marked and divided into 4 equal sections (2 sections on each lid).
A corneal shield will be placed into the fornix prior to treatment.
Each section will be treated with the designated power setting in the following manner.
The probe will be inserted into the follicle under direct visualization to a depth of approximately 1.4 mm.
The designated power will be applied for 1 second.
All lashes in each segment will be treated.
The segments will then be excised and placed into labelled and coded containers of formalin.
|
|
Experimental: 2 power
These tissue sections will receive radiofrequency ablation to each eyelash follicle at a power of 2.
|
The eyelid segments to be excised as part of their planned lateral tarsal strip procedure will be marked and divided into 4 equal sections (2 sections on each lid).
A corneal shield will be placed into the fornix prior to treatment.
Each section will be treated with the designated power setting in the following manner.
The probe will be inserted into the follicle under direct visualization to a depth of approximately 1.4 mm.
The designated power will be applied for 1 second.
All lashes in each segment will be treated.
The segments will then be excised and placed into labelled and coded containers of formalin.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Extent of tissue damage
Time Frame: Through study completion, approximately 6 months
|
The extent of damage will be measured on the tissue sections.
The diameter of abnormal/damaged tissue will be measured in microns.
|
Through study completion, approximately 6 months
|
|
Severity of tissue damage
Time Frame: Through study completion, approximately 6 months
|
The severity will be graded on a scale from 0 to 3, with 0 being no tissue changes and going up to 3 which will represent severe tissue changes.
|
Through study completion, approximately 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Priya Sahu, MD, Ochsner Health System
- Principal Investigator: Jayne Weiss, MD, Louisiana State University Health Sciences Center
Publications and helpful links
General Publications
- Nakamoto, D., Bernardino, C.R. The Annoying Lash in the Eye: A Review of Trichiasis. Review of Ophthalmology. Retrieved from: https://www.reviewofophthalmology.com/article/the-annoying-lash-in-the-eye-a-review-of-trichiasis. 2007.
- Kim GN, Yoo WS, Kim SJ, Han YS, Chung IY, Park JM, Yoo JM, Seo SW. The effect of 0.02% mitomycin C injection into the hair follicle with radiofrequency ablation in trichiasis patients. Korean J Ophthalmol. 2014 Feb;28(1):12-8. doi: 10.3341/kjo.2014.28.1.12. Epub 2014 Jan 21.
- Kezirian GM. Treatment of localized trichiasis with radiosurgery. Ophthalmic Plast Reconstr Surg. 1993 Dec;9(4):260-6. doi: 10.1097/00002341-199312000-00006.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00000551
- LSU IRB (Other Identifier: 19-016)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Trichiasis
-
Al-Azhar UniversityCompletedCicatricial TrichiasisEgypt
-
London School of Hygiene and Tropical MedicineCompleted
-
Massachusetts Eye and Ear InfirmaryLondon School of Hygiene and Tropical Medicine; University of Pennsylvania; The... and other collaboratorsCompletedEye Diseases | Eyelid Diseases | Trichiasis | Trachomatous Trichiasis (TT) | TrachomatousEthiopia
-
University of North Carolina, Chapel HillUniversity of Maryland, Baltimore; National Eye Institute (NEI); OrbisCompletedSurgery | TrichiasisEthiopia
-
Shahid Beheshti University of Medical SciencesOphtalmic Research CentreUnknownTrichiasisIran, Islamic Republic of
-
University of North Carolina, Chapel HillInternational Agency for the Prevention of BlindnessCompleted
-
University of North Carolina, Chapel HillUniversity of Maryland, Baltimore; National Eye Institute (NEI); OrbisCompleted
-
Johns Hopkins UniversityLions Club International FoundationCompletedTrichiasisUnited States
-
Johns Hopkins UniversityNational Eye Institute (NEI); Project ORBISCompletedTrichiasisUnited States
-
London School of Hygiene and Tropical MedicineCompletedTrachoma | Trachomatous TrichiasisEthiopia
Clinical Trials on Radiofrequency ablation
-
University Hospital, GhentUniversitaire Ziekenhuizen KU Leuven; AZ Sint-Jan AVRecruitingBenign Thyroid NoduleBelgium
-
Xijing HospitalUnknown
-
Assistance Publique - Hôpitaux de ParisTerminatedHepatocellular CancerFrance
-
Innoblative Designs, Inc.RecruitingBreast Cancer | Breast-conserving Surgery | Breast Cancer - Infiltrating Ductal Carcinoma | ER/PR+Her2neu | Grade I, II, IIIUnited States
-
McMaster UniversityWithdrawn
-
University Hospital, ToulouseCompletedPrimary Aldosteronism | Adrenal AdenomaFrance
-
Gaziler Physical Medicine and Rehabilitation Education...CompletedKnee OsteoarthritisTurkey (Türkiye)
-
Mansoura UniversityUnknownChronic Knee OsteoarthritisEgypt
-
Oxford University Hospitals NHS TrustRoyal Bournemouth and Christchurch Hospitals NHS Foundation TrustCompleted
-
Allevio Pain Management ClinicRecruitingShoulder Pain Chronic | Faceto-genic Neck Pain | Faceto-genic HeadacheCanada